Gujarat Themis Biosyn (GUJTHEM) Fundamentals 2026 — P/E 82.1x, Revenue Analysis | SniperIQ
Gujarat Themis Biosyn (GUJTHEM) is a India-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₹3,833 Crore, trading at ₹351.75 on the BSE. This SniperIQ fundamentals page covers Gujarat Themis Biosyn's valuation (P/E 82.1x, P/B 13.3x), profitability (net margin 28.2%), revenue (₹166 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Gujarat Themis Biosyn's market cap?
Gujarat Themis Biosyn (GUJTHEM) has a market capitalization of approximately ₹3,833 Crore, trading at ₹351.75 on the BSE. Market cap moves with the live share price.
What is Gujarat Themis Biosyn's P/E ratio?
Gujarat Themis Biosyn's trailing twelve-month P/E ratio is 82.1x, with a price-to-book (P/B) of 13.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Gujarat Themis Biosyn?
Gujarat Themis Biosyn runs a net profit margin of 28.2%, a gross margin of 62.6%, and an operating margin of 37.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Gujarat Themis Biosyn generate?
Gujarat Themis Biosyn reported revenue of ₹166 Crore for fiscal year 2026, with net income of ₹47 Crore and earnings per share (EPS) of 4.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Gujarat Themis Biosyn pay a dividend?
Gujarat Themis Biosyn offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Gujarat Themis Biosyn financially healthy?
Gujarat Themis Biosyn carries a debt-to-equity ratio of 0.56x and a current ratio of 1.12x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Gujarat Themis Biosyn a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gujarat Themis Biosyn (GUJTHEM) the key facts are: market cap ₹3,833 Crore, P/E 82.1x, revenue ₹166 Crore, 52-week range 225.75-479.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Gujarat Themis Biosyn's full fundamentals live
Get Gujarat Themis Biosyn's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.